TY - JOUR
T1 - Human mucopolysaccharidosis IIID
T2 - Clinical, biochemical, morphological and immunohistochemical characteristics
AU - Jones, Margaret Z.
AU - Alroy, Joseph
AU - Rutledge, Joseph C.
AU - Taylor, John W.
AU - Alvord, Ellsworth C.
AU - Toone, Jennifer
AU - Applegarth, Derek
AU - Hopwood, John J.
AU - Skutelsky, Ehud
AU - Ianelli, Christopher
AU - Thorley-Lawson, David
AU - Mitchell-Herpolsheimer, Cynthia
AU - Arias, Albert
AU - Sharp, Peter
AU - Evans, W.
AU - Sillence, David
AU - Cavanagh, Kevin T.
PY - 1997/10
Y1 - 1997/10
N2 - Mucopolysaccharidosis IIID (MPS IIID) is one of the rarest of the MPS- III syndromes. To date, the clinical manifestations of 10 patients have been reported, the deficient N-acetylglucosamine 6-sulfatase (G6S) enzyme has been purified, and the G6S gene has been cloned, sequenced and localized. However, morphological manifestations of this condition have not been reported and the pathogenesis of the severe neurological deficits remains an enigma. In this paper we describe and correlate the clinical, biochemical and pathological observations for 2 cases of MPS IIID. We used monoclonal antibodies against heparan sulfate (HS) and G(M2)-ganglioside, thin layer chromatography, mass spectrometry, and morphological techniques to demonstrate the nature and the distribution of the uncatabolized substrates. The majority of the cells in various tissues showed morphological changes expected with lysosomal storage of HS. The central nervous system (CNS) was most severely affected because of the secondary storage of G(M2) and G(M3) gangliosides in addition to the primary accumulation of HS. The extent as well as the distribution of the diverse storage materials varied within and among different neurons as observed in MPS-III A, B, and C syndromes. This study supports the hypothesis that the neurological dysfunction and neurodegeneration common to the Sanfilippo syndromes is, in part, due to the secondary metabolic perturbations induced by HS accumulation.
AB - Mucopolysaccharidosis IIID (MPS IIID) is one of the rarest of the MPS- III syndromes. To date, the clinical manifestations of 10 patients have been reported, the deficient N-acetylglucosamine 6-sulfatase (G6S) enzyme has been purified, and the G6S gene has been cloned, sequenced and localized. However, morphological manifestations of this condition have not been reported and the pathogenesis of the severe neurological deficits remains an enigma. In this paper we describe and correlate the clinical, biochemical and pathological observations for 2 cases of MPS IIID. We used monoclonal antibodies against heparan sulfate (HS) and G(M2)-ganglioside, thin layer chromatography, mass spectrometry, and morphological techniques to demonstrate the nature and the distribution of the uncatabolized substrates. The majority of the cells in various tissues showed morphological changes expected with lysosomal storage of HS. The central nervous system (CNS) was most severely affected because of the secondary storage of G(M2) and G(M3) gangliosides in addition to the primary accumulation of HS. The extent as well as the distribution of the diverse storage materials varied within and among different neurons as observed in MPS-III A, B, and C syndromes. This study supports the hypothesis that the neurological dysfunction and neurodegeneration common to the Sanfilippo syndromes is, in part, due to the secondary metabolic perturbations induced by HS accumulation.
KW - Gangliosides
KW - Heparan sulfate
KW - Mucopolysaccharidosis- IIID
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=0030982544&partnerID=8YFLogxK
U2 - 10.1097/00005072-199710000-00010
DO - 10.1097/00005072-199710000-00010
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0030982544
SN - 0022-3069
VL - 56
SP - 1158
EP - 1167
JO - Journal of Neuropathology and Experimental Neurology
JF - Journal of Neuropathology and Experimental Neurology
IS - 10
ER -